Viking Therapeutics, Inc.

Welcome to the Viking Therapeutics Second Quarter 2026 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press the star key followed by 1 on your touch-tone phone. If anyone has difficulty hearing the conference, please press the star 0 for operator assistance. And as a reminder, this conference call is being recorded today, July 29, 2026. I would now like to turn the conference over to Vikings Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.

Hello, and thank you all for participating in today's call. Joining me today is Brian Land, Vikings President and CEO, and Greg Zanti, Vikings CFO. Before we begin, I'd like to caution that comments made during this conference call today, July 29, 2026, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Vikings' expectations regarding its development activities, timelines, and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings for the Securities and Exchange Commission concerning these and other matters. I'll now turn the call over to Brian Leon for his initial comments.

Thanks, Stephanie, and good afternoon to everyone listening in by phone or on the webcast. Today we'll review our financial results for the second quarter and six months ended June 30, 2026, and review recent updates across our pipeline programs and organization. During the second quarter, we continued to advance each of the programs within our expanding obesity franchise. With respect to our lead compound, VK2735, a dual agonist of the GLP-1 and GIP receptors, Viking's Phase III Vanquish clinical program continued on track. The Vanquish program includes two studies. Vanquish 1, evaluating the treatment of adults with obesity, and Vanquish 2, evaluating the treatment of adults with obesity and type 2 diabetes. Both trials are fully enrolled, and during the second quarter, both proceed to advance according to plan. Also during the second quarter, the company continued preparing for the initiation of a Phase 3 program to evaluate the oral tablet formulation of VK2735. This program will consist of two studies, and will generally mirror the Vanquish Phase III program for the subcutaneous formulation. During the second quarter, our team continued to make progress toward initiation of these important studies, which are expected to begin in the fourth quarter of this year. During the second quarter, Viking also continued to execute its novel maintenance dosing study of BK2735. This range-finding study is designed to explore a variety of dosing regimens to identify suitable doses for further evaluation. The maintenance study leverages VK2735's unique in vivo profile and will assess the effects of weekly, monthly, and every other week regimens to identify those that may best support the individualized and long-term care often required to achieve and sustain a healthy weight. We expect to report the results of this study later this quarter. Finally, during the second quarter, Viking expanded its clinical stage obesity portfolio with the initiation of a Phase I single ascending dose trial of VK3019, an investigational dual amylin and calcitonin receptor agonist. We are excited to have this new program in clinical development, which we believe may offer another important potential treatment option for patients with obesity. I'll have additional comments on our operations and development activities following a review of our financial results for the second quarter and six months ended June 30th. For that, I'll turn the call over to Greg Zanti, Vikings Chief Financial Officer.